Back

The efficacy and safety of GLP-1 agonists to modify cardiovascular morbidity in patients with obesity without diabetes mellitus: a meta-analysis involving 32,884 patients

1 September 2024 (14:00 - 14:50)
Organised by: Logo
Congress Presentation Part of: Real-world evidence on the cardiovascular effects of therapies for diabetes Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Mohamed Abouzid

Poznan University of Medical Sciences, Poznan (Poland)

8 More presentations in this session

Presentation thumbnail
Cardiometabolic outcomes in patients with overweight and obesity undergoing weight loss trials : a network meta-analysis
Mr B. Tan (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
The effect of metformin use on the risk of atrial fibrillation in patients with type 2 diabetes: data from the UK biobank
Doctor T. Guo (Xi'an, CN)
Abstract Slides Video
Presentation thumbnail
The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after one year of observation.
Doctor S. Maragkoudakis (Chania, GR)
Abstract Slides Video
Presentation thumbnail
All cause mortality in people with type 2 diabetes using SGLT-2 inhibitors compared to DPP4 inhibitors using the danish registries
Doctor P. Yazdanfard (Hilleroed, DK)
Abstract Slides Video
Presentation thumbnail
Empaglifozin modifies the arterial stiffness in type-2 diabetic patients: a preliminary report.
Doctor M. Feola (Mondovi, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Real-world evidence on the cardiovascular effects of therapies for diabetes

The Event

Event poster

ESC Congress 2024

1 September 2024 14:00 CET
You may be interested in
thumbnail
Congress Presentation
GLP-1 RAs reduce mortality and cardiovascular events across the spectrum of treated patients: a systematic review and meta-analysis
thumbnail
Congress Presentation
The effect of Glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in type 2 diabetes mellitus patients with coronary artery disease
thumbnail
Congress Presentation
Primary prevention of heart failure with glucagon-like peptide-1 receptor agonist

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources